Broach Lifecare

Why is Broach Lifecare Hospital Ltd falling/rising?

As of 01-Sep, Broach Lifecare Hospital Ltd's stock price is stable at 18.20, with no recent price movement. Despite a strong monthly gain of +21.41%, the stock is underperforming its sector and showing declining investor interest, leading to a cautious outlook.

As of 01-Sep, Broach Lifecare Hospital Ltd's stock price is currently stable at 18.20, showing no change (0.00%). Over the past week, the stock has not experienced any price movement, reflecting a performance of +0.00%, while the benchmark Sensex has declined by -0.92%. In the past month, the stock has risen by +21.41%, significantly outperforming the Sensex, which fell by -1.47%. <BR><BR>Despite this positive monthly performance, the stock is currently underperforming its sector by -0.29%. Additionally, there has been erratic trading, as the stock did not trade on 2 out of the last 20 days. The stock's moving averages indicate that it is performing higher than the 5-day, 20-day, 50-day, and 100-day moving averages, but lower than the 200-day moving average, suggesting mixed signals regarding its longer-term trend.<BR><BR>Investor participation appears to be declining, with delivery volume dropping by -72.22% compared to the 5-day average, indicating reduced interest from investors. However, the stock remains liquid enough for trading, based on its average traded value. Overall, while the stock has shown a strong performance over the past month, the current lack of price movement, declining investor participation, and underperformance relative to its sector may contribute to a cautious outlook.

What does Broach Lifecare do?

Broach Lifecare Hospital Ltd, a micro-cap company incorporated in 2023, operates in the hospital industry after acquiring Dr. Jaykumar Narendra Vyas's healthcare facilities. It currently reports no sales or profits, with a market cap of INR 11 Cr.

Overview:<BR>Broach Lifecare Hospital Ltd operates in the hospital industry and is classified as a micro-cap company.<BR><BR>History:<BR>The company was incorporated in 2023 as "Broach Lifecare Hospital Private Limited" on April 25, 2023. It subsequently acquired the sole proprietorship concerns of Dr. Jaykumar Narendra Vyas, including Dr. Vyas's Heart Hospital and Dr. Vyas Hospital, through a Business Transfer Agreement dated July 17, 2023. There are no reported sales or profits for the latest quarter.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 11 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 123.00<BR>Industry P/E: N/A<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -0.07<BR>Return on Equity: 0.93%<BR>Price-to-Book: 1.14<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the peers of the Broach Lifecare?

Broach Lifecare's peers include Fortis Malar, Shanmuga Hospital, Soni Medicare, KK Shah Hospital, Global Longlife, Docmode Health, Nidan Laboratories, Aatmaj Health, Sangani Hospital, and Maitreya Medica. Most peers exhibit below average management and growth risks, with KK Shah Hospital showing the highest 1-year return at 9.39% and Global Longlife the lowest at -55.47%.

Peers: The peers of Broach Lifecare are Fortis Malar, Shanmuga Hos., Soni Medicare, KK Shah Hospital, Global Longlife, Docmode Health, Nidan Laborator., Aatmaj Health, Sangani Hospital, and Maitreya Medica.<BR><BR>Quality Snapshot: Below Average management risk is observed at Fortis Malar, Soni Medicare, KK Shah Hospital, Global Longlife, Broach Lifecare, Docmode Health, Nidan Laborator., and Maitreya Medica, while Average management risk is found at Shanmuga Hos. and Aatmaj Health. Excellent growth is noted at Sangani Hospital, while Below Average growth is seen at Fortis Malar, Shanmuga Hos., Soni Medicare, KK Shah Hospital, Global Longlife, Broach Lifecare, Docmode Health, Nidan Laborator., and Maitreya Medica, and Average growth is present at Aatmaj Health. Good capital structure is held by KK Shah Hospital, Broach Lifecare, Aatmaj Health, and Sangani Hospital, while Below Average capital structure is noted at Fortis Malar, Soni Medicare, Global Longlife, Docmode Health, Nidan Laborator., and Maitreya Medica.<BR><BR>Return Snapshot: The peer with the highest 1-year return is KK Shah Hospital at 9.39%, while Global Longlife has the lowest at -55.47%. Broach Lifecare's 1-year return is not specified, but it is positioned between these two extremes. Additionally, Global Longlife and Fortis Malar have negative six-month returns.

How big is Broach Lifecare?

As of 31st August, Broach Lifecare Hospital Ltd has a market capitalization of 11.00 Cr, classifying it as a Micro Cap company, with no available financial data for net sales or net profit for the latest four quarters. The latest annual report shows Shareholder's Funds of 9.36 Cr and Total Assets of 10.92 Cr.

As of 31st August, <BR><BR>Market Cap: Broach Lifecare Hospital Ltd has a market capitalization of 11.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for net sales or net profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The latest annual reporting period is March 2025, with Shareholder's Funds amounting to 9.36 Cr and Total Assets valued at 10.92 Cr.

Which are the latest news on Broach Lifecare?

When is the next results date for Broach Lifecare Hospital Ltd?

The next results date for Broach Lifecare Hospital Ltd is 21 May 2026.

The next results date for Broach Lifecare Hospital Ltd is scheduled for 21 May 2026.

Is Broach Lifecare overvalued or undervalued?

As of November 17, 2025, Broach Lifecare is considered very attractive and undervalued with a PE ratio of 19.11, significantly lower than its peers, indicating strong growth potential despite a year-to-date stock performance lagging behind the Sensex.

As of 17 November 2025, Broach Lifecare's valuation grade has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently assessed as undervalued, with a PE ratio of 19.11, an EV to EBIT ratio of 9.65, and a Price to Book Value of 1.07. These metrics suggest that Broach Lifecare is trading at a lower valuation compared to its peers in the healthcare sector.<BR><BR>In comparison to its peers, Broach Lifecare's PE ratio of 19.11 is notably lower than Apollo Hospitals at 64.41 and Narayana Hrudaya at 48.72, both of which are considered expensive. Additionally, the PEG ratio for Broach Lifecare stands at 0.00, indicating strong growth potential relative to its price, especially when contrasted with peers like Max Healthcare, which has a PEG ratio of 2.30. Despite the company's recent stock performance lagging behind the Sensex, with a year-to-date return of -21.3% compared to the Sensex's 8.72%, the underlying valuation metrics suggest that Broach Lifecare presents a compelling investment opportunity at its current price of 17.00.

How has been the historical performance of Broach Lifecare?

Broach Lifecare's historical performance from March 2024 to March 2025 shows increased net sales and shareholder equity, but a decline in profitability metrics and negative cash flow from investing activities indicate financial challenges.

Answer:<BR>The historical performance of Broach Lifecare shows a mixed trend in financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Broach Lifecare reported net sales of 3.18 Cr, an increase from 2.61 Cr in the previous year. Total operating income also rose to 3.18 Cr from 2.61 Cr, while total expenditure increased to 2.35 Cr from 1.58 Cr. Operating profit (PBDIT) decreased to 0.88 Cr from 1.03 Cr, leading to a decline in profit before tax to 0.72 Cr from 0.93 Cr. Consequently, profit after tax fell to 0.54 Cr from 0.70 Cr. The earnings per share (EPS) dropped to 0.89 from 1.57, reflecting a decrease in profitability. On the balance sheet, shareholder's funds grew to 9.36 Cr from 5.47 Cr, and total liabilities increased to 10.92 Cr from 5.72 Cr. The company reported a cash flow from financing activities of 4.00 Cr, consistent with the previous year, while cash flow from investing activities showed a negative trend at -3.00 Cr, worsening from -1.00 Cr. Overall, while Broach Lifecare experienced growth in sales and shareholder equity, profitability metrics and cash flow from operations indicate challenges in maintaining financial health.

Who are the top shareholders of the Broach?

The top shareholder of Broach is Jaykumar Narendra Vyas, holding 63.75% of the shares, with no pledged promoter holdings. The highest public shareholder is Kaushik Bhupatrai Joshi at 5.27%, while individual investors collectively own 33.77%.

The top shareholders of Broach include the promoters, with Jaykumar Narendra Vyas holding the largest share at 63.75%. There are no pledged promoter holdings, and mutual funds and foreign institutional investors do not hold any shares in the company. The highest public shareholder is Kaushik Bhupatrai Joshi, who owns 5.27%. Additionally, individual investors collectively hold 33.77% of the shares.

Has Broach declared dividend?

No Dividend History Available